雷贝拉唑、奥美拉唑治疗老年性反流性食管炎的临床效果分析

Analysis on clinical effectiveness of rabeprazole and omeprazole on senile reflux esophagitis

目的研究雷贝拉唑、奥美拉唑治疗老年性反流性食管炎的临床效果及用药安全性。方法选取2014年12月~2016年1月我院所收治的118例老年性反流性食管炎患者作为研究对象,按随机数字表法分为研究组和对照组,每组59例,对照组患者采取奥美拉唑联合西沙必利治疗,研究组患者采取雷贝拉唑与西沙必利联合治疗,对比分析两组患者的临床治疗效果。结果对照组患者出现胸骨后疼痛1例,反酸1例,合计发生率3.39%(2/59),研究组患者无一例出现胸骨后疼痛,反酸1例,合计发生率1.69%(1/59),两组比较,差异无统计学意义(P>0.05)。第4周和第8周检查结果显示:研究组的总有效率优于对照组,第4周结果两组比较差异有统计学意义,第8周无统计学意义,两组患者治疗期间无明显不良反应发生,且无明显肝肾功能异常。结论雷贝拉唑应用于老年性反流性食管炎的治疗中效果显著,能够有效改善患者的临床症状,促进炎症愈合,安全性较好,值得推广应用。

Objective To investigate the clinical effectiveness of rabeprazole and omeprazole on senile reflux esophagitis and analyze the safety of two drugs. Methods 118 patients with senile reflux esophagitis in our hospital from December 2014 to January 2016 were selected and randomized into study group and control group with 59 patients in each by using random number table. Patients in control group were treated with omeprazole and cisapride while patients in study group were treated with rabeprazole and cisapride. Clinical effectiveness and healing condition of two groups were compared, analyzed and verified. Results There were one case with retrosternal pain and one case with acid flux in control group. The total proportion of patients with retrosternal pain and acid flux was 3.39%（2/59）. There was no case with retrosternal pain and one case with acid flux in study group. The total proportion of patients with retrosternal pain and acid flux was 1.69%（1/59）. The total proportions of patients with retrosternal pain and acid flux in two groups were not statistically different. The test results of 4 th week and 8 th week showed： the total rate of effectiveness in study group was higher than that in control group, and there was significant difference between results of 4 th week in two groups while there was no significant difference between results of 8 th week in two groups. There were no complications and abnormalities in function of liver and kidney in patients of two groups. Conclusion The effectiveness of rabeprazole on senile reflux esophagitis was significant. It could improve the syndromes of patients and promote the healing of inflammation. It was with high safety as well. Thus, it was worth promotion.